Cartesian Therapeutics Inc (NASDAQ:RNAC)’s traded shares stood at 0.3 million during the last session, with the company’s beta value hitting 0.60. At the close of trading, the stock’s price was $24.52, to imply an increase of 7.45% or $1.7 in intraday trading. The RNAC share’s 52-week high remains $42.60, putting it -73.74% down since that peak but still an impressive 52.45% since price per share fell to its 52-week low of $11.66. The company has a valuation of $585.78M, with an average of 0.14 million shares in intraday trading volume over the past 10 days and average of 118.98K shares over the past 3 months.
Cartesian Therapeutics Inc (NASDAQ:RNAC) trade information
After registering a 7.45% upside in the last session, Cartesian Therapeutics Inc (RNAC) has traded red over the past five days. The 5-day price performance for the stock is 44.24%, and 74.64% over 30 days. With these gigs, the year-to-date price performance is 18.56%. Short interest in Cartesian Therapeutics Inc (NASDAQ:RNAC) saw shorts transact 2.05 million shares and set a 26.1 days time to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The extremes give us $40 and $45 for target low and target high price respectively. As such, RNAC has been trading -83.52% off suggested target high and -63.13% from its likely low.
Cartesian Therapeutics Inc (RNAC) estimates and forecasts
Looking at statistics comparing Cartesian Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Cartesian Therapeutics Inc (RNAC) shares are 84.22% up over the last 6 months, with its year-to-date growth rate higher than industry average at 55.53% against 17.60%. Revenue is forecast to grow 59.40% this quarter before jumping 98.20% for the next one. The rating firms project that company’s revenue will grow 71.00% compared to the previous financial year.
Revenue forecast for the current quarter as set by 7 analysts is 2.54M. Meanwhile, for the current quarter, a total of 7 analyst(s) estimate revenue growth to 2.64M.Earnings reports from the last fiscal year show that sales brought in 6.55M and 8.27M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -61.20% before dropping -68.10% in the following quarter.
RNAC Dividends
Cartesian Therapeutics Inc has its next earnings report out on 2024-Nov-11. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
